SecBot SecBot
8-K ·Filed Jun 23, 2026

TLPH

TALPHERA, INC.
NEUTRAL
Impact 2/10
Horizonweeks Processed4mo ago SEC0001437749-26-021446
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine annual meeting outcome. No immediate trading catalyst. Monitor next 10-Q for any equity grants made under the newly approved plans, which could indicate future dilution.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
TLPH ▲ +10.38% at T+60d
NEUTRAL call +10.38% · α vs SPY +7.54% · entry $1.06 → $1.17
Entry = T+0 close
Jun 23, 2026
via day close
T+1d
+0.94%
call +0.94% · α +0.80%
$1.07
settled 4mo ago
T+5d
-0.94%
call -0.94% · α -2.65%
$1.05
settled 4mo ago
T+20d
+21.70%
call +21.70% · α +19.77%
$1.29
settled 3mo ago
T+60d
+10.38%
call +10.38% · α +7.54%
$1.17
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Talphera reported the results of its 2026 Annual Meeting on June 22, 2026, at which all five stockholder proposals passed, including the election of three Class III directors (Marina Bozilenko, Joseph Todisco, Mark Wan), ratification of BPM LLP as auditor, advisory approval of executive compensation, and approval of amendments to the 2020 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan. These are routine governance and compensation matters with no material financial impact.

Key Facts

  • Elected Marina Bozilenko, Joseph Todisco, and Mark Wan as Class III directors until 2029
  • Ratified BPM LLP as independent auditor for FY2026 (31,019,362 votes for, 356,608 against)
  • Advisory say-on-pay passed (22,874,586 for, 786,249 against)
  • Stockholders approved amendment and restatement of 2020 Equity Incentive Plan (22,602,504 for, 1,068,623 against)
  • Stockholders approved amendment and restatement of 2011 Employee Stock Purchase Plan (23,020,334 for, 657,322 against)
  • 31,436,937 of 51,899,648 outstanding shares (60.6%) voted at the meeting

Financial Impact

No material financial impact; equity plan amendments authorize additional shares for employee compensation but exact dilution from new awards is not specified.

dilution

Risk Factors

  • Potential future dilution from equity awards granted under the amended 2020 EIP (share reserve up to 8,561,395 shares plus up to 744,608 returning shares)
  • No financial or operational performance data disclosed in this filing; stock price likely to react to future earnings or pipeline catalysts

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-021446
Exhibit: ex_979678.htm0001437749-26-021446
Document: acrx20260622_8k.htm0001437749-26-021446
Document: 0001437749-26-021446-index-headers.html0001437749-26-021446
Document: 0001437749-26-021446-index.html0001437749-26-021446
Document: 0001437749-26-021446.txt0001437749-26-021446

US Market Status

Market Closed — Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 23, 2026